Long-term sequelae in survivors of childhood leukemia with Down syndrome: A Childhood Cancer Survivor Study report Journal Article

Authors: Goldsby, R. E.; Stratton, K. L.; Raber, S.; Ablin, A.; Strong, L. C.; Oeffinger, K.; Sklar, C. A.; Armstrong, G. T.; Robison, L. L.; Bhatia, S.; Leisenring, W. M.
Article Title: Long-term sequelae in survivors of childhood leukemia with Down syndrome: A Childhood Cancer Survivor Study report
Abstract: BACKGROUND: Children with Down syndrome (DS) are at increased risk of developing acute leukemia and are more prone to acute toxicities. We studied the incidence and severity of chronic health conditions among survivors of childhood leukemia with DS compared with those without DS. METHODS: Chronic health conditions reported by questionnaire were compared between 154 pediatric leukemia survivors with DS and 581 without DS, matched by leukemia, age at diagnosis, race/ethnicity, sex, radiation location and chemotherapy exposure using Cox models to estimate hazard ratios (HRs) and 95% confidence intervals (CIs). Subjects were selected from 7139 5-year survivors of leukemia in the Childhood Cancer Survivor Study. RESULTS: Risk of at least 1 late onset chronic health condition (grade 1-5) was similar in the DS population compared with the non-DS group (HR, 1.1; 95% CI, 0.7-1.5). Serious chronic health conditions (grade 3-5) were more common in DS survivors (HR, 1.7; 95% CI, 1.1-2.6), as were ≥ 3 chronic health conditions (grades 1-5) (HR, 1.7; 95% CI, 1.2-2.4). The 25-year cumulative incidence of any condition (grades 1-5) was 83% for DS survivors and 69% for non-DS survivors. CONCLUSION: Leukemia survivors with DS have therapy-related chronic health conditions comparable to those of similarly treated survivors without DS, with a few notable exceptions: 1) an increased risk of cataracts, hearing loss, and thyroid dysfunction compared with survivors without DS (though these are known risks in the DS population), 2) decreased risk of second cancers, and 3) increased risk of severe or multiple conditions. Practitioners should be aware of these risks during and after therapy. Cancer 2018;124:617-25. © 2017 American Cancer Society. © 2017 American Cancer Society
Keywords: adolescent; adult; child; controlled study; school child; leukemia; major clinical study; cancer risk; cancer incidence; cohort analysis; cyclophosphamide; retrospective study; late effects; questionnaire; population research; disease severity; whole body radiation; survivorship; cataract; sex difference; age distribution; second cancer; anthracycline derivative; childhood leukemia; race difference; hearing impairment; ethnicity; thyroid disease; down syndrome; childhood cancer survivor; human; male; female; priority journal; article; chronic conditions
Journal Title: Cancer
Volume: 124
Issue: 3
ISSN: 0008-543X
Publisher: Wiley Blackwell  
Date Published: 2018-02-01
Start Page: 617
End Page: 625
Language: English
DOI: 10.1002/cncr.31065
PROVIDER: scopus
PMCID: PMC5780223
PUBMED: 29105081
Notes: Article -- Export Date: 6 February 2018 -- Source: Scopus
Altmetric Score
MSK Authors
  1. Charles A Sklar
    283 Sklar
  2. Kevin Oeffinger
    266 Oeffinger